The UK is the first country to introduce a dedicated law to decentralise manufacturing of personalised medicines at the point ...

Amid a season of regulatory and scientific advances, experts reveal a culture of data hoarding among cell and gene therapy ...

Research and development collaboration program to include additional models of lymphoma and leukemia to further validate ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

From cell-manufacturing laboratories to outpatient infusion facilities, health systems are rapidly adapting to a new kind of cancer treatment that demands individualized care, infrastructure and ...

Cellular Origins, the Cell and Gene Therapy Catapult, and Resolution Therapeutics have formed a consortium funded by Innovate ...

Joel Eichmann discusses the challenges of scaling adherent cell culture and the innovations helping to streamline the ...

The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new ...

The alliance brings together Cellular Origins, a company focusing on applying robotics and other forms of automation to CGT ...

Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly ...

This how to guide explores integrated strategies and technologies that support consistent, efficient and scalable cell therapy manufacturing.

Our Bureau, Mumbai Friday, July 18, 2025, 17:45 Hrs [IST] ...